Immutep Ltd has released a press release.
Immutep doses First Patient in TACTI-002 Phase II Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- TACTI-mel data presented at World Immunotherapy Congress
- Half Year Accounts
- Immutep enters into collaboration with CYTLIMIC
- Cleansing prospectus for issue of warrants
- European patent granted for IMP321 & antibody combinations
Later from Immutep
- IMP761 results presented at ECCO conference
- Immutep granted US patent for IMP321
- More mature positive data for TACTI-mel trial presented
- Immutep granted European patent for eftilagimod alpha
- First patient dosed in INSIGHT-004
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep